Treatment of primary IgA nephropathy  by Alexopoulos, Efstathios
Kidney International, Vol. 65 (2004), pp. 341–355
NEPHROLOGY FORUM
Treatment of primary IgA nephropathy
Principal discussant: EFSTATHIOS ALEXOPOULOS
Hippokration General Hospital, Thessaloniki, Greece
CASE PRESENTATION
A 36-year-old man was referred to the Department
of Nephrology at the Hippokration General Hospital
of Thessaloniki because of an episode of asymptomatic
gross hematuria concomitant with febrile gastroenteritis
3 weeks before presentation. Subsequently, several uri-
nalyses revealed persistent microscopic hematuria and
proteinuria. Two years ago, he had noted an additional
episode of “tea-colored” urine accompanied by a flu-like
illness, but no further investigation was carried out. He
had no family history of renal disease.
Physical examination on admission was unremarkable.
Chest, abdomen, and extremities were normal. There was
no rash or arthritis. His blood pressure was 140/95 mm
Hg, the pulse rate was normal at 78 beats/min, and his
temperature was 36.8◦C. Neither dysuria nor oliguria
was present. He did not complain of pain or discomfort
in his lumbar region. No eye or ear abnormalities were
detected.
Laboratory investigation revealed hemoglobin,
14 g/dL; glucose, 90 mg/dL; blood urea, 32 mg/dL; serum
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creatinine, 1.1 mg/dL; sodium, 140 mEq/L; potassium,
4.2 mEq/L; calcium, 9.5 mg/dL; phosphorus, 3.5 mg/dL;
total protein, 6.8 g/dL; albumin, 4.1 g/dL; cholesterol,
274 mg/dL; triglycerides, 160 mg/dL; uric acid, 4.6 mg/dL;
and alanine aminotransferase, 20 U/L. Glomerular
filtration rate (GFR) estimated by plasma clearance of
51Cr-EDTA was 115 mL/min. Serum markers for HBV,
HCV, and HIV were negative. Serum immunoglobulins
and complement were normal. Serum protein elec-
trophoresis was normal and cryoglobulins were negative.
No clotting abnormalities were detected. A search for
ANA, anti-DNA, and ANCA antibodies was negative.
The antistreptolysin titer was less than 100 U/mL.
Ultrasonography disclosed two normal nonobstructed
kidneys. Urinalysis revealed 50 to 60 red blood cells/high
power field and few leukocytes. Approximately 80% of
the urinary erythrocytes were dysmorphic. The 24-hour
urinary protein excretion was 2.2 g. Urine cultures were
sterile.
A percutaneous renal biopsy contained 20 glomeruli
by light microscopy. One glomerulus was globally scle-
rotic. The remaining glomeruli manifested moderate to
marked mesangial cell proliferation and matrix expan-
sion with focal accentuation of the lobular pattern. Focal
mesangial cell interposition and duplication of the base-
ment membranes, usually with luminal narrowing, also
were present. A few neutrophils infiltrated the glomeruli.
No crescents or segmental necrotizing lesions were seen.
Focal areas of tubular atrophy affecting less than 15%
of the tubular cross-sections and mild interstitial fibrosis
also were present. No significant vascular abnormalities
were noted. Immunofluorescence study showed diffuse
mesangial deposition of IgA and C3. Focal capillary wall
staining by IgA also was present.
The patient was given perindopril (4 mg/day) and
fish oil supplements (Maxepa, Seven Seas, Ltd. Hull,
England, UK) in a dosage of 3 capsules twice daily,
which provided 0.85 g of eicosapentaenoic acid and 0.57 g
of docosahexaenoic acid. Over the following 6 months,
his blood pressure became normal (110/70 mm Hg),
his serum creatinine remained essentially unchanged
(1.0 mg/dL), and the proteinuria decreased to 420 mg/
24 hours. Then he deliberately discontinued the fish oil
therapy. Five months later he visited our clinic again. His
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blood pressure had been well controlled with perindopril
(120/80 mm Hg). The serum creatinine was normal (1.1
mg/dL) but proteinuria had increased to 1.2 g/24 hours.
He was prescribed fish oil again in addition to antihyper-
tensive treatment. During the subsequent several months
his proteinuria gradually decreased to 310 mg/24 hours.
The patient was last examined 3 months ago, almost
9 years after diagnosis. His blood pressure was 125/80 mm
Hg. Urinalysis revealed 10 to 15 red blood cells/high
power field. The serum creatinine was 1.2 mg/dL; GFR by
51Cr-EDTA, 109 mL/min; and the 24-hour urine protein
excretion, 370 mg. Therapy with perindopril (4 mg/day)
and fish oil was continued.
DISCUSSION
Dr. Efstathios Alexopoulos (Associate Professor of
Medicine and Nephrology, Department of Nephrology,
Hippokration General Hospital, Thessaloniki, Greece):
This case represents one of the most typical clinical
presentations of primary IgA nephropathy (IgAN) and
raises issues relating to prognosis and treatment of the
most common form of primary glomerulonephritis world-
wide. Two Nephrology Forums in the last decade or so
have expertly addressed the pathogenesis of the disease
and its immunogenetic associations [1, 2]. In today’s pre-
sentation, I will provide an overview of the progress made
in the prognosis and treatment of IgAN, focusing on
the current status of various therapeutic approaches and
the data upon which recommendations regarding their
use are based.
Patients with IgAN usually present with hematuria [3–
5]. Approximately 40% to 50% of patients have macro-
scopic hematuria frequently accompanied by an infection
of the upper respiratory tract and, less often, pneumonia,
gastroenteritis, or urinary tract infection. The episode is
usually brief—about 24 hours—but can last as long as
1 week. This presentation usually occurs in children and
in patients under 40 years of age, and loin pain often
accompanies the hematuria. Microscopic hematuria, usu-
ally with proteinuria, constitutes the other common initial
presentation in another 30% to 40% of patients. Macro-
scopic hematuria can complicate the course of about 20%
to 25% of patients in this subgroup. This presentation is
more common in older patients but is observed in patients
of all ages. As many as 20% of patients with IgAN present
with severe azotemia that represents long-standing dis-
ease. Acute renal failure occurs in less than 10% of
patients, and the nephrotic syndrome is uncommon,
occurring only in approximately 5% of all patients, usu-
ally children and adolescents [6].
The diagnosis of IgAN currently can be made only by
kidney biopsy. The spectrum of light microscopic findings
ranges from minor mesangial changes to focal and diffuse
mesangial proliferation to crescentic glomerulonephritis.
Table 1. Clinical risk factors for progression in IgA nephropathy
(IgAN)
Impaired renal function at discoverya
Magnitude and duration of proteinuriaa
Hypertension at presentationb
Older age at onset
Absence of recurrent macrohematuria
Persistent microscopic hematuria
Male gender
Obesity
Hyperuricemia
Hypertriglyceridemia
Smoking
Familial disease
aMost significant independent predictors by multivariate analysis in almost all
studies (reviewed in [8]).
bSignificant by univariate analysis in almost all studies and by multivariate
analysis in some (reviewed in [8]).
In addition to glomerular lesions, various tubulointer-
stitial and vascular lesions also can be seen, including
tubular atrophy, interstitial fibrosis, interstitial cellular
inflammation, and vascular sclerosis. However, the
histopathologic criterion for IgAN is the dominance or
co-dominance of IgA deposition in the mesangium [5, 7].
Although many other diseases also are associated with
glomerular IgA deposits [5], I will not consider their prog-
nosis and treatment in this review.
Clinical course and prognosis
The course of primary IgAN is highly variable, ranging
from a totally benign condition to rapidly progressive re-
nal failure. In a small fraction of patients, progression is
rapid and associated with necrotizing glomerulitis and ex-
tensive crescent formation [8]. The majority of patients,
however, have a slowly progressive decline in renal func-
tion over 10 to 20 years [8]. The wide variability in clinical
course has been addressed in a number of reviews from
around the world. The actuarial renal survival at 10 years
reported by the majority of studies in Europe, Asia, and
Australia is 81% to 87% [8–10]. However, poor renal
survival rates, 67% and 57%, respectively, have been re-
ported in two studies from the United States; these rates
probably refer to more advanced renal disease at the time
of diagnosis [11, 12].
Factors that predict the rate of progression of the dis-
ease have been identified over the last 10 years, and
these include clinical, histologic, and genetic parameters
(Tables 1 and 2). Multivariate analysis according to the
Cox model confirmed that an elevated serum creatinine
level at presentation and heavy proteinuria are power-
ful independent predictors of poor outcome [8] (Fig. 1).
However, some caution should be exercised in liberally
translating initial renal function as a prognostic tool. For
poorly understood reasons, even patients with modest
impairment of renal function (for example, serum cre-
atinine 1.5 to 2.0 mg/dL) can exhibit long periods free
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Fig. 1. Survival free of renal failure in patients with IgA nephropathy (IgAN) according to serum creatinine (A) and proteinuria (B) at renal biopsy.
(Reprinted from [11] with permission.)
Table 2. Histologic risk factors for progression in IgA nephropathy
(IgAN)
Glomerular
Advanced glomerulosclerosisa
Mesangial hypercellularity
Segmental necrotizing lesions
Extensive crescents (>30%)
Capillary wall deposits of IgA
Tubulointerstitial
Marked tubulointerstitial fibrosisa
Intense interstitial infiltration
Arteriosclerosis/arteriolosclerosis
aStrong independent predictors by multivariate analysis of all reported series
(reviewed in [8]).
from progression, particularly in the presence of trivial
or modest proteinuria [13]. On the other hand, as many
as 7% to 10% of patients with minimal proteinuria and
normal renal function at presentation can progress to
end-stage renal disease (ESRD) over the long term [ab-
stract; Wong TU et al, J Am Soc Nephrol 11:77A–78A,
2001]. Nevertheless, patients with a slowly progressive
course and a serum creatinine above 3.0 mg/dL seem
to have passed the “point of no return” and will al-
ways progress to ESRD without remission, even with
therapy [14].
The magnitude and character of proteinuria are power-
ful clinical indicators of an adverse outcome. At present,
I believe that no sharp dividing point relates the mag-
nitude of proteinuria to prognosis. Most investigators,
however, believe that more than 1 g/day is a reason-
able threshold for concern [11, 15]. Universal consen-
sus exists that proteinuria >3 g/day is associated with a
high likelihood of a subsequent progressive decline in
renal function [11]. The presence of significant quan-
tities of low-molecular-weight proteins (for example,
a1-microglobulin) in addition to albumin and gamma
globulin, probably increase the likelihood for progres-
sive disease or a poorer response to treatment [16],
possibly because of the severity of the underlying tubu-
lointerstitial damage, in addition to the primary glomeru-
lar disease.
Less concordant are the data for the prognostic value
of arterial hypertension at presentation. High blood pres-
sure (>140/90 mm Hg) can be an important factor asso-
ciated with a more rapid progression in adults with IgAN
[11, 17]. However, when this clinical factor was evaluated
using multivariate analysis in several studies, it appeared
to be significant in some but not all (reviewed in [8]).
Additional clinical and laboratory parameters that
have been independently associated with progression
have been recently identified (reviewed in [18]). These in-
clude persistent complement C3 activation, elevated lev-
els of C-reactive protein, excessive weight or body mass
index, hypertriglyceridemia and hyperuricemia, long-
term occupational exposure to volatile hydrocarbons,
dietary habits, and family history of nephritis. Male gen-
der, older age at onset, absence of episodes of macro-
scopic hematuria, and persistent microscopic hematuria
also have been associated with progression in some stud-
ies [11, 15, 17].
Renal histology can be a powerful tool that can aid
in the estimation of progression. Different scoring sys-
tems have identified mesangial hypercellularity, global
or segmental glomerulosclerosis, extracapillary prolifer-
ation, segmental necrotizing lesions, interstitial fibrosis,
and vascular lesions as markers of a poor prognosis [11,
12]. In multivariate analysis, however, only the severity
of glomerulosclerosis and interstitial fibrosis appear to
be strong independent predictors of a progressive course
[8]. The identification of different types of cells, mediator
molecules, growth factors, or cell differentiation antigen
in renal biopsies by specific immunohistochemical tech-
niques also has added to the precision of histologic prog-
nostication [19–22].
Immunogenetic factors such as human leukocyte anti-
gen associations (for example, HLA-B35) do not seem
to be helpful in predicting prognosis [2]. In addition, the
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results of initial positive studies on the association be-
tween polymorphism of the angiotensin-converting en-
zyme (ACE) gene and progression of IgAN have not
been confirmed in follow-up studies [23]. Data on other
candidate genes are fragmentary.
These outcome studies illustrate that different clini-
cal and pathologic prognostic markers or the composite
of clinicopathologic determinants at the time of diagno-
sis can be used to predict patients with IgAN who are
at risk for progression. However, candidate factors and
their prognostic values vary from one study to another,
and none has been widely accepted. More important,
for the majority of the patients, prognostic indicators
are weak on an individual basis. Even with clinical or
histologic scoring systems, the predictive value reaches
statistical significance only with larger cohorts. Nonethe-
less, attempts at relating these factors in a way that
will provide better prognostication in individual patients
have met with some success. For example, Bartosik et al
[24] constructed a formula to predict subsequent change
in GFR using data on urinary protein excretion and mean
arterial blood pressure over 2 to 3 years of observation in
298 patients with IgAN. This formula only accounted for
about one-third of the total variability in progression. In-
terestingly, pathology was not an independent predictor
of outcome in this study. Many factors other than protein-
uria and blood pressure undoubtedly participate in deter-
mining the long-term outcome of IgAN. In the future, the
development of methods assessing the activity of the dis-
ease likely will help provide more accurate prognosis of
IgAN. At present, clinical and pathologic features should
be considered complementary with respect to assessment
of prognosis and selection of candidates for therapeutic
intervention.
Treatment
In the 1980s, the role of IgAN as a major cause of ESRD
was firmly established. In the 1990s, the focus of clinical
studies has shifted from defining the natural history of the
disease to the development of therapeutic strategies. The
therapeutic nihilism prevalent in the early years following
the initial description of IgAN seems to be giving way in
the 21st century to a modicum of optimism. But this view
is based on small trials with a short follow-up, differences
in study design and statistical evaluation, and inclusion
of heterogeneous populations of patients. Carefully con-
ducted, randomized, prospective trials are still few, and
side-by-side comparisons of therapies thought to be effec-
tive are lacking. One also must keep in mind an important
caveat: namely, that the underlying pathogenesis of IgAN
remains poorly understood and, as a consequence, most
therapeutic efforts are empiric in nature or are based on
unproved assumptions regarding disease mechanism.
Should all patients with IgAN be treated? Given the
usually benign course of patients with normal renal func-
tion, minimal (<1.0 g/day) or no proteinuria, normal
blood pressure, and minimal or mild lesions on renal
biopsy, there is widespread consensus not to offer spe-
cific treatment to such patients but rather to keep them
under periodic review [25]. On the other hand, patients
with one or more adverse prognostic features such as
hypertension, proteinuria >1 g/day, slowly progressive
renal failure, and moderate to severe changes in renal
biopsy histology could be candidates for one or even sev-
eral therapeutic modalities [4, 5, 25]. We will now look
at the current approaches to treating adults with primary
IgAN and arrive at my recommendations for treatment.
ACE inhibitors. Control of blood pressure remains
the cornerstone of treatment as for patients with other
types of kidney disease [26, 27]. The therapeutic bene-
fit of antihypertensive drugs is thought to be a putative
reduction of glomerular hypertension that provides pro-
tection against glomerular injury. Because of their ability
to specifically reduce intraglomerular pressure, ACE in-
hibitors have attracted the most attention as the ideal an-
tihypertensive drugs for the treatment of hypertension in
renal disease, including IgAN. The effectiveness of ACE
inhibitors in reducing progression of renal dysfunction is
posited to be a consequence of their antiproteinuric effect
rather than attributable to their blood- pressure-lowering
effect alone. Moreover, ACE inhibitors also might atten-
uate the effect of angiotensin II on renal cell growth and
proliferation and might inhibit extracellular matrix com-
ponent release that culminates in sclerosis [29].
The relative therapeutic efficacy of ACE inhibitors
over other antihypertensive drugs in IgAN is supported
by some, but not all, studies. In a trial by Rekola,
Bergstrand, and Bucht [30] in 56 patients with IgAN and
hypertension, 22 patients were treated with enalapril, and
34 patients treated with beta blockers served as controls.
After 1.7 years of follow-up, renal function was stable in
the enalapril-treated group but deteriorated in the beta
blocker–treated group despite equivalent blood pressure
control levels. A similar beneficial effect on renal func-
tion of ACE inhibitors also has been demonstrated in
two small studies in patients with IgAN and either nor-
mal renal function [26] or progressive disease [31]. How-
ever, no change in proteinuria was observed in these
studies.
In contrast, two randomized clinical trials found that
a variety of ACE inhibitors moderately lowered uri-
nary protein excretion without improving renal function
[32, 33]. Interestingly, Maschio et al [32] showed that
ACE inhibitors reduced proteinuria even in normoten-
sive patients with IgAN. An additional large, retrospec-
tive cohort study by Cattran, Greenwood, and Ritchie
[34] suggested a slower rate of decline in renal func-
tion and a higher percentage of remission of proteinuria
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when hypertension accompanying IgAN was treated with
ACE inhibitors as compared with other antihypertensive
agents. They observed maximal benefit in retarding pro-
gression in patients with proteinuria >3 g/day, and the
beneficial effects stongly correlated with the extent to
which proteinuria decreased with treatment. However,
we here in Thessaloniki have not been able to confirm
the superiority of ACE inhibitors over other antihyper-
tensive treatments either in reducing proteinuria or pre-
serving renal function in patients with IgAN of mild to
moderate severity [35].
Despite the apparent discrepancies among the results
of different studies, ACE inhibitors are used widely in
the treatment of patients with IgAN who have significant
proteinuria or hypertension, both of which are consid-
ered modifiable risk factors for progressive disease [36].
Whether these agents also are beneficial in nonhyperten-
sive or nonproteinuric patients remains uncertain. Some
investigators have suggested that the ACE/DD geno-
type is a marker for an up-regulated renin-angiotensin
system that causes a more rapid progression of IgAN
and that ACE inhibitors might improve renal function in
patients who possess the ACE/DD polymorphism [37].
These findings have not yet been consistently confirmed,
however.
The role of angiotensin II receptor blockers (ARBs)
is not yet firmly established. Perico et al [38] demon-
strated that enalapril and irbesartan are equally effec-
tive in reducing proteinuria in patients with IgAN. The
combination of losartan and ACE inhibitors appeared
to have an additive effect on the reduction of protein-
uria, whereas doubling the dose of monotherapy had no
effect [39]. These short-term studies, however, did not
demonstrate a blood pressure–independent reduction in
proteinuria, and the combination therapy has not been
proven to be more antiproteinuric than a combination of
ACE inhibitors or ARBs with any other antihypertensive
agent. In addition, the renoprotective effect in these trials
has been difficult to separate from the blood pressure–
lowering effect, and it is not clear whether this combi-
nation preserves renal function more effectively than do
ACE inhibitors alone [40].
Hopefully, the specific role of ACE inhibition in the
treatment of IgAN will be clarified by large-scale tri-
als, which are currently underway in the United States
and Europe [41, 42]. Other agents, such as beta block-
ers and nondihydropyridine calcium antagonists, appear
to have some antiproteinuric potential, which correlates
with the magnitude of decline in blood pressure, whereas
dihydropyridines might not have a similar beneficial pro-
file [25]. What should be the goal of treatment with
ACE inhibitors and/or ARBs in IgAN? The consensus
is that blood pressure should be reduced to the lowest
value obtainable without inducing side effects, certainly
≤130/80 mm Hg [18, 25]. If this target is not achievable
with an ACE inhibitor or ARB, a nondihydropyridine
calcium channel antagonist should be added. Although it
is not clear what threshold of proteinuria corresponds to
an increased risk of progressive renal failure, lowering the
protein excretion from baseline to <1.0 g/day might be
preferable. Adding an ARB to an ACE inhibitor might
be more effective in this regard. In clinical practice, how-
ever, this goal might not be achievable in the majority of
the patients. Thus I believe that adult patients with per-
sistent proteinuria (for example, >1 g/day), despite ade-
quate treatment with an ACE inhibitor and/or an ARB,
can be considered for more aggressive therapy [25].
Steroids. Steroids were among the first agents used for
the treatment of IgAN. In an early, randomized, prospec-
tive, controlled trial in adult patients with IgAN and the
nephrotic syndrome, 4 months of therapy with moder-
ate doses of oral steroids did not produce any benefit
except in patients with very mild histologic lesions [43].
Also, Kobayashi et al [44, 45] reported beneficial effects
of steroids given in moderate doses for periods of 1 to
3 years in patients with moderate or heavy proteinuria.
In both studies, renal function was preserved in patients
with an initial creatinine clearance of >70 mL/min but
not in those with more severe impairment of renal func-
tion. The same authors also have demonstrated that daily
steroids for 18 months in IgAN patients with normal re-
nal function and moderate proteinuria produced a better
preservation of renal function and a greater reduction in
proteinuria 10 years after therapy when compared with
an untreated group [46].
In a recent Italian multicenter prospective study [47],
86 adult patients with IgAN, proteinuria of 1.0 to 3.5 g/day,
and a serum creatinine below 1.5 mg/dL were randomly
assigned to supportive or steroid therapy (intravenous
methylprednisolone, 1 g/day for 3 days at the beginning
of months 1, 3, and 5 accompanied by oral prednisone
0.5 mg/kg every other day for months 1 to 6). Pretreat-
ment renal histology, serum creatinine, and proteinuria
did not differ between the groups. After 5 years of follow-
up, 21% of the steroid-treated patients had a doubling of
serum creatinine from baseline values, whereas 33% of
the patients in the untreated group experienced a similar
rise in serum creatinine (P < 0.05). Proteinuria signifi-
cantly decreased in the steroid-treated group to 40% of
baseline values; it remained unchanged in the untreated
group. An interesting finding in this study was the loss of
the significant benefit of steroid therapy on renal func-
tion after reduction in proteinuria at 6 months was added
to the multivariate analysis as a covariate. These studies
strongly suggest that in patients with IgAN accompanied
by moderate to heavy proteinuria but reasonably well-
preserved renal function, long-term steroid treatment
(6 months to 2 years) protects against subsequent pro-
gression by reducing the magnitude of proteinuria. More
prolonged treatment with steroids appeared no more
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effective in the long-term protection of renal function
[abstract; Kobayashi Y et al, J Am Soc Nephrol 13:680A,
2002]. The effect of steroids might be related to their abil-
ity to reverse proliferative lesions in the early phase of
the disease and prevent fibrosis [48]. However, patients
with impaired renal function and more severe pathologic
changes on renal biopsy appear to respond less favor-
ably to steroids alone, despite claims to the opposite [49].
These patients could be considered for more aggressive
therapy. Certainly, steroids are indicated for patients with
the nephrotic syndrome and minimal change lesions on
biopsy. I’ll return to this topic in a moment.
Immunosuppressive drugs. There is limited expe-
rience with the use of azathioprine in the treatment
of IgAN in adults. Goumenos et al [50] published a
retrospective study that used long-term azathioprine
combined with low-dose prednisone in patients with
progressive renal disease accompanied by proteinuria
and moderate to severe histologic changes. Eighty per-
cent of patients receiving azathioprine exhibited sta-
ble renal function, but only 36% of the group treated
conservatively. There was no effect on proteinuria. In-
terestingly, however, approximately one-third of patients
who had features suggestive of a high likelihood of pro-
gression remained stable, even with persistently impaired
renal function. Extending their observations at 10 years,
the same authors found no differences in the overall
clinical course between treated and untreated patients
[51]. However, treatment with prednisolone and azathio-
prine appeared to be beneficial in a subgroup of patients
with heavy proteinuria (>3 g/day), baseline serum crea-
tinine between 1.4 and 2.5 mg/dL, and histologic lesions
of moderate severity. No effect was observed in pa-
tients with more advanced renal failure (serum creatinine
>2.5 mg/dL) and severe histologic lesions. Serious side ef-
fects were frequently seen, however. Controlled trials are
needed to confirm these data before this treatment is rec-
ommended. Such a multicenter trial comparing steroids
plus azathioprine with steroids alone is in progress in Italy
[52].
Cyclophosphamide has been used in a limited number
of trials. Some of these studies used a combination of
cyclophosphamide, dipyridamole, and warfarin [53, 54]
and chiefly showed a reduction in proteinuria. A con-
sistent protective effect on renal function could not be
demonstrated, however. Because of the multiplicity of the
combinations used, it is difficult to ascertain whether the
results were due to cyclophosphamide or the other com-
ponents. Furthermore, the 6-month treatment with cy-
clophosphamide was associated with significant gonadal
dysfunction, making this therapy unacceptable in young
patients. Interestingly, in a recent retrospective study in
patients with moderately advanced IgAN, the combi-
nation of low-dose cyclophosphamide with steroids and
antiplatelet agents significantly reduced proteinuria and
better preserved renal function as compared with patients
treated with antiplatelet drugs alone [55]. Adverse effects
related to the immunosuppressive drugs were identified
in 14% of the patients, but no case of gonadal toxicity was
noted. Until results of additional trials are available, cy-
clophosphamide should not be used in patients with IgAN
of mild or moderate severity [27]. However, cyclophos-
phamide might have a therapeutic role in patients with
severe glomerular inflammation and extensive crescent
formation.
Cyclosporine was tested in a randomized single-blind
trial conducted by Lai, Lai, and Vallance-Owen [56]. The
drug was given for 12 weeks to 24 patients with protein-
uria of at least 1.5 g/day and reduced renal function. They
showed a modest reduction in proteinuria, unfortunately
often accompanied by a rise in serum creatinine. These
changes were reversed after cessation of the treatment.
Thus, while cyclosporine is likely to display an antipro-
teinuric effect in IgAN, the risk of nephrotoxicity limits
its usefulness. Limited trials of mycophenolate mofetil
(MMF) have been reported. In a few case reports and a
small uncontrolled trial, MMF, 1 to 2 g/day alone or com-
bined with steroids for several months, decreased pro-
teinuria and stabilized serum creatinine in patients with
severe IgAN [57]. Also, in a recent small study in patients
with severe IgAN, treatment with MMF for 1 year pro-
duced a more effective reduction in proteinuria, higher
rate of complete remission, and better preservation of re-
nal function as compared with a 1-year course of steroid
therapy [abstract; Chen X et al, J Am Soc Nephrol 13:14A,
2002]. These findings are too limited to draw any defini-
tive conclusion. Several regional and multicenter clinical
trials are underway to further evaluate this therapy.
Little information is available about the role of other
immunosuppressive strategies in IgAN. Rostoker et al
[58] studied the effects of high-dose intravenous im-
munoglobulins in an uncontrolled study with 11 pa-
tients with IgAN or Henoch-Scho¨nlein purpura who had
moderate to severe histologic lesions, heavy proteinuria
(>2 g/day), and rapid deterioration of renal function.
After treatment, proteinuria decreased modestly and
the rate of decline in GFR decreased from 3.78 mL/
min/month to 0 mL/min/month. Repeat renal biopsy re-
vealed a reduction in the activity index and a decrease in
the staining intensity of glomerular IgA and C3 deposits.
This might be a promising approach, especially in patients
with a relatively rapid course of declining renal function.
Whether similar beneficial effects would be obtained in
patients with milder or more slowly progressive disease
is as yet unknown.
Fish oil. Interest in fish oil as a treatment of IgAN
has recently intensified. Fish oil is rich in x-3 fatty acids,
eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA). These compete with arachidonic acid and
produce biologically less-effective prostaglandins and
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leukotrienes that might retard renal damage by decreas-
ing glomerular and interstitial inflammation, platelet ag-
gregation, and vasoconstriction [5]. Twenty years ago,
Hamazaki, Tateno, and Shishido [59] reported in a pre-
liminary trial involving 20 patients with IgAN that the
treatment group who received fish oil for 1 year main-
tained a stable renal function as opposed to untreated
controls. Since then, two randomized controlled trials [60,
61] have failed to demonstrate any beneficial effect of 1.8–
3.3 g/day of EPA combined with 1.2–1.8 g/day of DHA.
Most of these studies were relatively short term and in-
volved small numbers of patients. However, a study of
106 patients in a double-blind, placebo-controlled trial
from the Mayo Clinic provided strong evidence of a pro-
tective effect of fish oil therapy [62]. This trial selected
patients with heavy proteinuria (average, 2 g/day) and
mildly impaired renal function (average serum creati-
nine, 1.5 mg/dL; creatinine clearance, 82 mL/min). Pa-
tients were treated with 1.8 g of EPA and 1.2 of DHA
daily for 2 years. By the end of treatment, 6% of the
fish oil–treated patients and 33% of the placebo group
had reached the study end point, a doubling of serum
creatinine. The annualized median decrease in creatinine
clearance was only 0.3 mL/min/1.73 m2 of body surface
area in patients treated with fish oil, as compared with
a decrease of 7.1 mL/min/1.73 m2 in patients given the
placebo. Interestingly, the authors noted no beneficial ef-
fect in urinary protein excretion. After observation for an
additional 2 years, the cumulative percentage of patients
who developed ESRD or died was 40% in the placebo
group versus 10% in the fish oil group [63]. The study
was criticized because of the rapid loss of renal function
in the placebo group but was as expected for patients
with baseline characteristics of a high likelihood of pro-
gressive disease. These results have been confirmed by
our recent prospective study in 44 patients with normal
or mildly impaired renal function [35]. Treatment with
fish oil for 4 years better preserved renal function. The
mean annual change in GFR was +1.7 ± 8.4 mL/min in
the treated group as compared with −4.8 ± 9.4 mL/min
in the untreated group (P < 0.05). Interestingly, protein-
uria decreased significantly only in the subgroup of pa-
tients treated with fish oil in combination with an ACE
inhibitor. A meta-analysis of all reported trials of fish oil
therapy in IgAN conducted by Dillon [64] concluded that
treatment with fish oil has a small, statistically insignifi-
cant benefit on renal function, with an estimated preser-
vation of creatinine clearance of 1 to 2 mL/min/year.
In a more recent, randomized, open-label, parallel-
group clinical trial, the same group of Mayo Clinic inves-
tigators demonstrated that doubling the dose of x-3 fatty
acids (3.76 g/day of EPA and 2.9 g/day of DHA) for 2 years
was equally effective in slowing the rate of renal func-
tion loss in high-risk patients with IgAN when compared
with the low-dose regimen employed in previous trials
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Fig. 2. Annual rate of change in serum creatinine (A) and glomeru-
lar filtration rate (B) in patients with severe IgA nephropathy (IgAN)
treated with fish oil. Mean values are indicated by the asterisk.
(Reprinted from [35] with permission.)
[65]. We also have tested the hypothesis whether an even
lower dose of x-3 fatty acids might be effective in pro-
gressive IgAN in a randomized, prospective controlled
trial [abstract; Alexopoulos E et al, Nephrol Dial Trans-
plant 17(Suppl 11):28, 2002]. Fourteen patients were as-
signed to receive a “very low” dose of fish oil (0.85 g/day
of EPA and 0.57 g/day of DHA) for 4 years; 14 patients
were treated symptomatically and used as controls. Dur-
ing treatment, one patient (7%) in the fish oil–treated
group and six in the control group (43%) had an increase
of 50% or more in serum creatinine (P < 0.01). The mean
annual change in GFR was significantly higher in the
control group (−3 mL/min) than in the fish oil–treated
group (−1.4 mL/min)(Fig. 2). Interestingly, proteinuria
was significantly lower in the treated patients at the end
of follow-up. Further investigations are needed to clar-
ify the discrepancy of results in clinical trials testing fish
oil and to determine the optimal dose. Nevertheless, it
remains a promising and safe approach for patients with
IgAN at risk for progression. Combinations of fish oil with
other regimens such as prednisolone or azathioprine, al-
though attractive, have not yet been tested for efficacy. In
the United States, a randomized controlled trial is under-
way comparing fish oil, alternate-day prednisolone, and
ACE inhibitors in children and young adults with IgAN
[41]. The results of this trial should considerably clarify
whether steroids or fish oil is better for patients at risk
for progressive renal disease.
Anticoagulant and antiplatelet drugs. Anticoagulant
and antiplatelet therapy have long been used in the treat-
ment of IgAN. Most of the early trials were uncontrolled
and small in size [53, 54]. In addition, many of the regi-
mens included steroids and/or cytotoxic agents, so inter-
pretation of the results was difficult. Lee et al [66] used a
combination of dipyridamole and low-dose warfarin for
3 years in 11 patients and 10 controls with serum cre-
atinine between 1.6 and 3.0 mg/dL. At the end of the
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trial, creatinine clearance was stable in the treated group
but had deteriorated in the control group. No changes
in proteinuria were noted. Administration of urokinase
demonstrated beneficial effects on renal function and
proteinuria early, but these effects were not sustained
over long-term follow-up [25]. Also, preliminary results
have shown a reduction in proteinuria in patients with ad-
vanced IgAN after long-term treatment with intravenous
heparin [abstract; Ho Y et al, J Am Soc Nephrol 13:458A,
2002]. At present the potential benefits of antiplatelet and
anticoagulant therapy remain unclear. However, these
approaches could be considered second-line therapy, es-
pecially in patients with contraindications or intolerance
to other forms of treatment [25].
Other treatment considerations. Numerous other ap-
proaches to the therapy of IgAN have been described.
These include the use of mizoribine, phenytoin, danazol,
sodium chromoglycate, 5-amino-salicylic acid, gluten-
free and low-antigen-content diets, hepatic 3-methyl-
glutaryl-coenzyme A reductase inhibitors, and doxycy-
cline. Most of these treatments have been recently re-
viewed in detail and appear to offer minimal, if any, long-
term benefit [25].
Tonsillectomy also has been recommended for patients
with IgAN, but its role remains controversial. Removal of
the tonsils in patients with chronic or recurrent tonsillitis
reduces serum IgA levels, circulating immune complexes,
proteinuria, and episodic hematuria. Patients most likely
to benefit from tonsillectomy had preserved renal func-
tion (serum creatinine <1.4 mg/dL) and mild changes on
histology. These benefits were not observed in patients
with more advanced renal disease [67].
Tonsillectomy in combination with pulse steroid ther-
apy might produce higher rates of clinical remission [68].
However, no study to date has shown long-term preser-
vation of renal function in patients who have undergone
tonsillectomy. Tonsillectomy has not yet been tested in
a controlled randomized trial, so this approach should
be reserved for recurrent episodes of macroscopic hema-
turia or relief of chronic recurrent tonsillitis [27].
Treatment of specific groups
IgAN associated with the nephrotic syndrome. The
nephrotic syndrome (NS) is an uncommon presentation
of IgAN [4]. Nephrotic patients with IgAN and mini-
mal change lesions on renal biopsy seem to respond to
steroids or have spontaneous remissions of the NS. In a
controlled trial in adults with IgAN presenting with the
NS and varying severity of histology on renal biopsy, the
use of 40 to 60 mg of prednisolone/day yielded a high
rate of remission of NS (80%) among patients with mild
glomerular histologic changes, but many patients expe-
rienced side effects [43]. The NS runs a course similar
to idiopathic minimal change disease, with relapses that
usually remain steroid-responsive. For patients intoler-
ant to steroids, long-term fish oil therapy in combina-
tion with ACE inhibitors has been recommended [25, 35].
Cyclophosphamide has been suggested for patients with
frequent relapses [25]. However, nephrotic patients with
more severe histologic features do not appear to bene-
fit from a short course of prednisolone. The best treat-
ment for this subset of IgA patients has not yet been de-
termined. More prolonged treatment with steroids [69]
or the combination of prednisolone with azathioprine
[51] has been recommended for IgA patients with heavy
proteinuria and less favorable renal histology. A meta-
analysis by Schena, Montenegro and Scivittaro in 1990
[70] also concluded that steroids and/or cytotoxic drugs
are beneficial when administered to patients with heavy
proteinuria whether or not it is associated with NS.
IgAN with a rapidly progressive course. This un-
common presentation usually occurs in association with
diffuse crescentic glomerulonephritis or following an
episode of macroscopic hematuria, when renal biopsy re-
veals minor glomerular changes but marked acute tubu-
lar necrosis and red cell casts in the tubules [69]. Because
of the rarity of patients with rapidly progressive crescen-
tic glomerulonephritis, no controlled therapeutic studies
have been undertaken. In sporadic reports and small se-
ries, pulse steroids, cytotoxic agents, anticoagulants, intra-
venous immunoglobulins, and MMF have been claimed
to stabilize the course of the disease, at least temporar-
ily [25, 27]. Habib, Niaudet, and Levy [71] found pulse
methylprednisolone beneficial in crescentic IgAN. The
combination of prednisolone and cytotoxic agents also
might benefit patients with extensive crescents [72]. In
a recent controlled trial in 38 patients with moderately
rapidly progressive disease, combined treatment with
prednisolone and oral cyclophosphamide for 3 months,
followed by azathioprine for 2 years or more, resulted in
better preservation of renal function and a lower degree
of proteinuria than did placebo [73].
The role of plasmapheresis in these patients is con-
troversial. Plasmapheresis added to steroids and cyto-
toxic agents stabilizes renal function during treatment
[74]. However, no consistent data exist on the course of
the disease following cessation of therapy; some stud-
ies report a deterioration of renal function, and others
note a sustained effect. Moreover, the usual combina-
tion of plasmapheresis with other drugs makes inter-
pretation of the results difficult. Until more data are
available, patients with crescentic IgAN and a rapidly
progressive course should be treated like those with
other forms of crescentic glomerulonephritis: they should
be given pulses of methylprednisolone followed by oral
prednisolone and oral cyclophosphamide [27]. Plasma-
pheresis also can be added in resistant cases or in dialysis-
dependent patients and can be tailored according to
the clinical progress of the patient. Patients with rapid
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progression with or without extensive crescents also can
be considered candidates for intensive intravenous im-
munoglobulin therapy [58].
Treatment of patients who present with macrohema-
turia and rapidly deteriorating renal function accompa-
nied by acute tubular lesions on renal biopsy is only
supportive, and no specific measures are recommended
[27]. Dialysis is indicated during the period of acute renal
failure, which is usually reversible. In rare cases in which
acute interstitial nephritis predominates, a short course
of oral steroids may be indicated.
Recurrence of IgAN after renal transplantation. Re-
nal transplantation is often required in the treatment
of patients with IgAN who progress to ESRD. After
transplantation, the disease recurs in 20% to 60% of
grafts, with the higher percentages reported from centers
that perform serial biopsies. Recurrence occurs equally
both in living related and cadaveric donor organ recip-
ients [4, 5]. However, the recurrence rate is somewhat
higher in recipients of living related kidneys, particularly
HLA-identical sibling grafts, than in recipients of cadaver
kidneys [75]. Initial reports considered recurrent IgAN a
relatively benign condition. In fact, the 5-year graft and
patient survival did not differ from patients with other
forms of glomerulonephritis who received renal grafts
[75]. It is now apparent, however, that recurrent IgAN is
not a benign condition. Starting at approximately 5 years
after transplantation, recurrent disease becomes a rele-
vant clinical problem and can cause a decline in renal
function and graft loss in as many as 15% of the grafts.
This graft loss is distinct from graft failure due, for ex-
ample, to allograft rejection [76]. Poorer 10-year survival
has been reported in patients with IgAN in the presence
of clinically apparent recurrent disease [77]. The interval
between transplantation and development of recurrence
of IgAN or significant loss of graft function is approxi-
mately 2 and 3 years, respectively.
Younger patients seem to be at higher risk of recur-
rence; HLA-2 antigen might play a protective role [77]. In
addition, no relationship was found between the aggres-
siveness of the primary disease and the rate of recurrence
of the disease [76]. Patients who lost a previous graft from
recurrent IgAN might be at higher risk for repeated graft
loss because of recurrence upon retransplantation [4].
The optimal approach for treating recurrent disease
has not been defined. Immunosuppression with corticos-
teroids, azathioprine, and/or cyclosporine A does not pre-
vent recurrence of the disease, either histologically or
clinically [4]. Whether MMF can prevent recurrence or be
effective in attenuating recurrent disease, as suggested by
a recent study [75], remains to be established. Also Oka
et al recently suggested that treatment of recurrence with
ACE inhibitors is beneficial [78].
Physicians and patients should be aware that recurrent
disease can induce graft loss even after 5 years and be-
yond. As recent data showed equal rates of recurrence in
cadaveric kidneys and kidneys from living related donors,
transplantation from living related donors should not be
discouraged [4, 5]. However, I do not believe that retrans-
plantation with living related kidneys should be encour-
aged for patients who have already lost a graft due to
recurrent IgAN.
Conclusions
For the moment, no consensus exists on the best treat-
ment of IgAN. Before making any therapeutic decisions,
clinicians should keep in mind the chronic nature of the
disease and the possibility of a good outcome without
therapy. Treatment, therefore, should be relatively non-
toxic and probably limited to patients who have reason-
able evidence of a poor long-term prognosis.
Hypertension should be treated aggressively, mainly
with ACE inhibitors or ARBs. General agreement ex-
ists that patients with normal renal function, no or trivial
proteinuria (<0.5 g/day), normotension, and minimal or
mild lesions on renal biopsy should be managed conser-
vatively with regular follow-up. It is not known whether
patients with proteinuria > 0.5 g/day but <1 g/day should
be treated. In my opinion, even if they are normotensive,
one should attempt to lower proteinuria to <0.5 g/day by
giving these patients fish oil and an ACE inhibitor or an
ARB.
Patients with greater proteinuria (>1 g/day), nor-
mal or mildly impaired renal function (serum creatinine
<1.4 mg/dL), and mild-to-moderate renal lesions should
initially receive fish oil in combination with an ACE in-
hibitor or ARB in an attempt to lower proteinuria to
<1 g/day. If this reduction cannot be achieved, then a
course of low-dose steroids on a daily or alternate-day
basis for 3 to 6 months is indicated. Whether the combi-
nation of these two therapies is more effective is not clear
as yet.
Patients with persistent proteinuria >1 g/day, impaired
renal function (serum creatinine >1.4 mg/dL), and mod-
erate to severe histologic changes are less likely to
respond to steroids. Again, these patients could be suc-
cessfully treated with fish oil in combination with ACE
inhibitors or ARBs, as indicated by the international
experience and our own. Alternatively, azathioprine or
MMF and low-dose alternate day prednisolone could be
considered. When contraindications to prednisolone or
immunosuppressive drugs exist, low-dose warfarin com-
bined with dipyridamole could be used.
Patients with NS and minimal glomerular changes ap-
pear to respond to steroids. For nephrotic patients with
more severe histologic changes, a combination of steroids
with immunosuppressive drugs is indicated, as they ap-
pear to respond less favorably to steroids alone. Fish oil
also might be effective in some of these patients.
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Patients with rapidly progressive crescentic glomeru-
lonephritis can benefit from steroids, either pulse
therapy or oral prednisolone in combination with
cyclophosphamide, and sometimes supplemented by
plasma exchange. High-dose intravenous immunoglobu-
lin therapy also might be of benefit in this group. Patients
with acute renal failure after a bout of macrohematuria
demonstrating a paucity of crescents (<30% segmental
crescents) on renal biopsy but predominantly tubuloint-
erstitial changes seem to spontaneously heal and recover
even if dialysis is required. Patients with chronic renal fail-
ure (serum creatinine>3 mg/dL) should be treated symp-
tomatically. Fish oil combined with an ACE inhibitor or
an ARB might stabilize progression in some of these
patients. For the moment, there is no specific therapy
for recurrent IgAN in renal allografts. The use of ACE
inhibitors might be beneficial and MMF might prevent
recurrent disease.
QUESTIONS AND ANSWERS
Dr. Nicolaos E. Madias (Dean ad Interim, Tufts Uni-
versity School of Medicine, Boston, Massachusetts, USA):
Currently, IgAN is being diagnosed only by renal biopsy.
What other diagnostic approaches might be used in
the future to better characterize the nature of the
nephropathy?
Dr. Alexopoulos: If one could design a sensitive
method for measuring the degree or character of abnor-
mal IgA1 galactosylation, the cytokine profile of patients’
peripheral blood lymphocytes, and/or the level of circu-
lating aggregates in the serum, theoretically it ought to
be a reasonable, noninvasive diagnostic test. However,
two key issues emerge as potential limitations. First, such
tests might be related to IgA deposition, or to suscepti-
bility to IgA deposition, rather than to IgAN per se. For
example, first-degree relatives of patients with IgAN have
abnormally high Th2 responses in vitro without evidence
of glomerular disease, even after close scrutiny [2]. On
the other hand, normal people can have some galactose-
deficient IgA1 in their circulation, and this can give rise
to false positives, which would destroy the test’s value as
a diagnostic tool for IgAN. Second, prognostic informa-
tion available at present from the biopsy might not derive
from the in vitro tests. Indeed, the correlation between
the levels of circulating immune complexes and severity
or course of glomerulonephritis in general has been par-
ticularly disappointing [7, 79]. In addition, it is worthwhile
to remember that aggregates in the circulation might rep-
resent a fraction that is less prone to glomerular deposi-
tion. Such tests, however, might be helpful in the future
in defining the prognosis or therapeutic response in pa-
tients with biopsy proven IgAN. Today, the only way to
diagnose IgAN is to do a renal biopsy.
Dr. Dimitrios Tsakiris (Director, Department of
Nephrology, General Hospital of Veria, Veria, Greece):
For many years, IgAN has been associated with respi-
ratory or gastrointestinal infections. Are there specific
antigens that trigger the pathogenetic mechanisms of the
disease?
Dr. Alexopoulos: Two types of antigens seem to be in-
volved in the pathogenesis of IgAN: environmental res-
piratory or gastrointestinal infectious agents and food
antigens. Antibodies to several viruses or bacteria (such
as cytomegalovirus, herpes simplex, hepatitis B, aden-
ovirus, Haemophilus parainfluenzae, Epstein-Barr virus,
and Escherichia coli) and dietary components (including
gluten, soy, cow milk, ovalbumin, and rice proteins) have
been detected in the mesangium of some patients with
IgAN usually, but not always, coincident with IgA1 de-
posits [80]. Nevertheless, the plethora of infectious and
inert antigens implicated in the pathogenesis of IgAN
have little in common, mitigating the likelihood of an in
situ mechanism of deposit formation [7]. Because similar
circulating antibodies specific to environmental antigens
are present in normal subjects as well as in patients with
IgAN, the array of deposited antibodies likely has little or
nothing to do with the nature of the particular antigens
[7]. Until now, no one has been able to unequivocally
identify specific antigens that are responsible for the for-
mation of IgA deposits in patients with IgAN.
Dr. George Sakellariou (Director, Department of
Nephrology, “Papageorgiou” Hospital, Thessaloniki,
Greece): I have been impressed by the effectiveness of in-
travenous immunoglobulins in the treatment of patients
with severe IgAN and rapidly declining renal function.
What is the potential mechanism by which these im-
munoglobulins act? Also, is there evidence of a similar
effect of intravenous immunoglobulins on the course of
chronic disease?
Dr. Alexopoulos: With regard to your first question,
intravenous immunoglobulins are effective in several
immune-mediated diseases. Numerous mechanisms have
been proposed to explain their beneficial action, but none
satisfactorily explains all clinical situations [81]. In IgAN,
abnormalities in the IgA immune system and a deficiency
in the IgG1 subclass might favor viral and bacterial infec-
tions [58]. Immunoglobulin therapy inhibits B-cell differ-
entiation and immunoglobulin production by acting on
the B-cell IgG Fc receptor and might regulate excessive
B-cell IgA production. Immunoglobulins also improve
T-suppressor function, which is deficient in this disease,
and modulate monocyte function, thus reducing cytokine
production. The immunoglobulins prevent active C3 frag-
ments from binding to target surfaces and the formation
of C5b-9, and they accelerate the decay of C3b to an
inactive form [58, 81]. Immunoglobulins also contain anti-
idiotypic antibodies that can either bind to and modu-
late the activity of autoreactive B and T cells or bind to
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circulating pathogenic antibodies. Finally, they restore
the serum IgG1 deficiency that can favor the expansion
of the medullary IgA B-cell compartment, which is in-
creased in IgAN [58, 81].
In regard to your second question, no data exist so far
on the use of this therapy in patients with chronic IgAN.
Although intravenous immunoglobulin therapy might be
a promising approach, one has to consider the high rate
of relapses after treatment is discontinued [58] and, of
course, the potential risks of such therapy [81].
Dr. Nicolaos Zoubaridis (Director, Renal Unit, General
Hospital of Edessa, Edessa, Greece): Could you tell us
a bit more about familial IgAN? How frequent is this
form of the disease? Are there differences in the clinical
course of the disease between familial and nonfamilial
(sporadic) cases?
Dr. Alexopoulos: The true frequency of familial IgAN
remains uncertain, but perhaps it accounts for about 10%
of all patients with the disease [18]. Schena, Scivittaro
and Ranieri [82] found urinary abnormalities in approxi-
mately 23% of 269 relatives from 48 families of IgAN pa-
tients, but this percentage might be even higher (>50%).
In addition, a variety of abnormalities of IgA immuno-
biology also were noted in these relatives. In a recent
multicenter study in which 30 kindreds of multiplex fam-
ilies with IgAN were studied, the investigators defined a
very strong linkage with the trait 6q22-23 in 60% of kin-
dreds, with a maximal likelihood of odds score of 5.6 [83].
More recently, Schena’s group also described two novel
loci on chromosomes 4 and 7 affecting the development
of the disease (personal communication). Such findings
support the suggestion that familial IgAN is a complex
disease initiated by one or more genes, probably in com-
bination with environmental conditions. Whether similar
genes are responsible for the progression of the disease
needs to be determined. Clinical findings at presentation
cannot distinguish sporadic cases from those with familial
disease [2]. It is interesting, however, that a recent report
demonstrated worse renal outcome in cases of familial
versus sporadic IgAN [84].
Dr. Dimitrios Vlahakos (Assistant Professor, De-
partment of Nephrology, Aretaieion Hospital, Athens,
Greece): What is the rationale for combining ACE in-
hibitors with ARBs?
Dr. Alexopoulos: The rationale for this combination
therapy is the assumption that ARBs would counteract
the AT1-mediated effect of residual angiotensin II forma-
tion by non-ACE enzymes like chymase, whereas ACE
inhibitors would additionally increase the level of kinins.
Furthermore, ACE inhibitors as well as ARBs would syn-
ergistically elevate the levels of angiotensin (1–7), which
also might promote vasodilation. Finally, combining both
drug classes might simply provide a higher degree of
blockade of the classic renin-angiotensin system path-
ways [85]. In a small study in selected patients with IgAN,
combination therapy demonstrated a greater antihyper-
tensive and antiproteinuric effect than did either drug
class alone [39]. Also, the recent “Cooperate” study that
included 131 patients with IgAN indicated that this com-
bination offers superior renoprotection over either ACE
inhibitor or ARB alone in non-nephrotic proteinuric re-
nal disease [86].
Dr. Vasilios Vargemezis (Professor of Nephrology, Uni-
versity of Thrace, Alexandroupolis, Greece): You men-
tioned that a combination of fish oil supplements with
an ACE inhibitor has a more potent antiproteinuric ef-
fect than either drug alone. Could you speculate on the
potential mechanism?
Dr. Alexopoulos: I am afraid I do not have a precise
answer to your question. I can offer a hypothesis, how-
ever. Experimental studies in rats subjected to subtotal
renal ablation demonstrated that fish oil therapy reduced
mean arterial pressure and efferent arteriolar resistance
and decreased glomerular capillary pressure [87]. Both
proteinuria and glomerulosclerosis were lessened by this
therapy. Fish oil might exert these hemodynamic effects
by reducing angiotensin II–dependent signaling events,
such as phospholipid hydrolysis, or by limiting synthesis
of the potent renal vasoconstrictor thromboxane A2. The
latter findings are reminiscent of those observed follow-
ing the administration of ACE inhibitors and thus support
the notion that these compounds act through a parallel
pathway [87]. Large-scale trials, some of which are under-
way, are needed to test this hypothesis. Regardless, our
results combined with the experimental data provide a
physiologic rationale that could potentially be applied to
the treatment of progressive IgAN.
Dr. Constantinos Sombolos (Director, Renal Unit,
“Papanicolaou” General Hospital, Thessaloniki): What
are the indications for treatment with steroids and/or
immunosuppressive agents? For how long should this
therapy be continued?
Dr. Alexopoulos: There are only two circumstances in
which steroid therapy is definitely indicated in IgAN: (1)
NS with mild glomerular changes on histology, and (2)
rapidly progressive crescentic glomerulonephritis where
steroids are used in combination with a cytotoxic agent
and/or plasmapheresis [69]. In other forms of the dis-
ease, steroids are recommended for patients with moder-
ate to heavy proteinuria (>2 g/day), well-preserved renal
function (creatinine clearance > 70 mL/min), and mild
histopathologic changes [45, 47]. For these patients, rela-
tively long-term steroid treatment (6 months to 2 years)
can have a beneficial effect, as shorter treatments seem
not to offer any particular benefit [25]. For patients with
more severe histologic lesions and impaired renal func-
tion (creatinine clearance < 70 mL/min) steroids alone
will not likely be of much benefit [25]. In this circum-
stance, combined treatment of steroids for 18 months
and azathioprine for 24 months might be more effective
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[51, 70]. For patients with rapidly progressive crescentic
glomerulonephritis, high-dose steroids combined with cy-
clophosphamide for 6 months is recommended [73]. We
do not know with a measure of certainty how long these
therapies should be continued. Perhaps long-term, ade-
quately sized trials combined with repeat biopsies will
determine the optimal duration of treatment with these
drugs.
Dr. Athanasios Agrafiotis (Director, Department of
Nephrology, “Asclepieion” General Hospital, Athens):
Do you stop fish oil treatment in patients who respond to
it?
Dr. Alexopoulos: No. Treatment with fish oil is contin-
ued in all patients unless they reach ESRD.
Dr. Athanasios Dimitriadis (Director, Department of
Medicine, “Aghios Dimitrios” Hospital, Thessaloniki):
Do we have treatments aiming at reducing the frequency
of episodic macrohematuria or the severity of micro-
scopic hematuria? Would you treat a patient with macro-
scopic hematuria but no significant proteinuria?
Dr. Alexopoulos: Although we have no specific ther-
apy for hematuria, several approaches are associated with
reductions in hematuria. Tonsillectomy has been asso-
ciated with a reduction in the episodes of macroscopic
hematuria, as well as in microscopic hematuria [88].
Phenytoin also reduced the number of episodes of macro-
hematuria [89]. Treatment with doxycycline (100 mg
daily) for 12 months decreased microscopic hematuria
to normal counts [90]. Finally, the use of steroids in sev-
eral studies reduced episodes of macroscopic hematuria
and led to the disappearance of microscopic hematuria
in a significant proportion of patients [91, 92]. Regarding
your second question, I would treat this particular pa-
tient if his biopsy revealed extensive crescent formation
or significant acute interstitial nephritis.
Dr. Charalambos Stathakis (Director, Department of
Nephrology, Laikon Hospital, Athens): Does tonsillec-
tomy affect long-term renal prognosis of IgA patients?
Which are the current recommendations for tonsillec-
tomy?
Dr. Alexopoulos: The role of tonsillectomy in the long-
term prognosis of IgAN remains unclear. In some studies,
no effect of tonsillectomy on disease progression could
be appreciated [67]. In a more recent retrospective study,
however, tonsillectomy was associated with better long-
term preservation of renal function and lower risk for
development of ESRD [93]. Clearly, a prospective con-
trolled study of the effect of tonsillectomy on the long-
term renal prognosis in patients with IgAN is needed.
Until more data are available, tonsillectomy might be rec-
ommended for treatment of recurrent episodes of macro-
scopic hematuria in conjunction with chronic tonsillitis
in patients with well-preserved renal function (serum
creatinine < 1.4 mg/dL) [25, 27]. However, since we
have no proof of efficacy in progressive disease, this ap-
proach cannot currently be recommended on a routine
basis.
Dr. Dimitrios Goumenos (Assistant Professor, Renal
Unit, University Hospital, Patras, Greece): You demon-
strated that widely accepted clinical and pathologic
prognostic factors, although useful in cohort studies,
cannot be easily applied for predicting outcome in in-
dividual cases. Do you think that other approaches based
on modern molecular biology that assess disease activ-
ity might be a more useful guide for identifying pa-
tients at risk for progression? Would you recommend
a repeat renal biopsy to estimate disease activity after
treatment?
Dr. Alexopoulos: Various mediator systems such as
cytokines, complement, chemokines, and growth factors
very likely influence the propensity for disease progres-
sion in a given individual. Several investigators have
demonstrated that, for example, the deposition of a-
smooth muscle actin in renal tissue [19], as well as the
presence of c d T cells and perhaps PCNA(+) infiltrates
within the interstitium have a prognostic importance [94].
Our group also has demonstrated the prognostic value
of increased expression of LFA-1 integrin and C5b-9
in early biopsies of patients with IgAN [22, 95]. Large
numbers of interstitial macrophages also were related to
poorer outcome [21]. Interestingly, the numbers of inter-
stitial macrophages were closely related to the amount
of MCP-1 excreted in the urine [abstract; Papagianni A
et al, XXXVII Cong ERA/EDTA, p 126, 2000]. Param-
eters such as the ratio of interleukin-6 (IL-6):epidermal
growth factor (EGF) in the urine or increased transform-
ing growth factor-b (TGF-b) excretion might be other ap-
proaches to refining prognosis [35, 96]. The identification
and characterization of these and other “progression-
associated” molecules in renal tissue or in the urine might
offer new ways for us to determine individual prognosis at
early stages of disease and to better assess disease activity.
Until these modern techniques are refined, I would rec-
ommend a repeat biopsy only in the context of research
projects or in patients with unexplained deterioration of
renal function.
Dr. Aikaterini Papagianni (Lecturer, Department of
Nephrology, Hippokration General Hospital, Thessa-
loniki): You did not mention how to manage patients with
proteinuria of more than 0.5 g/day but less than 1.0 g/day.
What would you suggest?
Dr. Alexopoulos: It is not known whether patients with
these values of protein excretion should be treated. We
must remember, however, that as many as 7% to 10%
of these patients will wind up with ESRD after sev-
eral years. Appel and Glassock [18] suggested the use
of ACE inhibitors and/or ARBs in this group of patients,
even if they are normotensive, in an attempt to lower
proteinuria to <0.5 g/day. In a recent prospective trial,
Praga et al [97] demonstrated better preservation of renal
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function in IgA patients whose proteinuria exceeded 0.5
g/day and who were treated with ACE inhibitors. The
authors suggest early initiation of treatment, when renal
function is still normal. My own policy is to treat these pa-
tients with a combination of fish oil and an ACE inhibitor;
in our experience, ACE inhibitors alone were not effec-
tive in patients with low-grade proteinuria.
Dr. Madias: Considering the ongoing advances in the
pathogenesis of IgAN and the mechanisms mediating dis-
ease progression, could you speculate on the future treat-
ment directions of this disease?
Dr. Alexopoulos: Future directions for treatment of
IgAN would probably include the modulation of the im-
mune response as well as enzymatic approaches. The in-
hibition of gene expression by antisense oligonucleotides
might be a potential therapeutic strategy. This treatment
might arrest the synthesis of abnormal IgA or block spe-
cific gene effects of cytokines involved in IgA synthe-
sis (that is, IL-5 and TGF-b) or inhibit or suppress the
synthesis of IgG (or IgA and IgM) antibodies specific
for truncated glycans. The aberration in IgA galactosyla-
tion might be diminished or abrogated by blockade of
one of the Th2 cytokines that underlies the abnormal
galactosylation or administration of an inhibitor [such
as interferon-gamma (IFN-c )] of the effects of the Th2
cytokines.
Truncated glycans might be selectively “repaired” by
the appropriate exogenous galactosyltransferase(s). In
addition, IgA aggregates in the circulation and/or in
the glomerular deposits might be irreversibly dissoci-
ated by proteolytic enzymes, such as IgA1 proteases.
These and other future therapeutic attempts have been
recently reviewed [98], but their efficacy awaits clinical
confirmation.
Dr. Parashos Koukoudis (Associate Director, Renal
Unit, General Hospital of Kilkis, Kilkis, Greece): You em-
phasized that recurrent IgAN in a kidney graft can result
in declining renal function and graft loss in about 15% of
the grafts despite immunosuppressive therapy. Do you
think fish oils have a place in the management of these
patients?
Dr. Alexopoulos: I have no personal experience, nor
am I aware of any published trials on the efficacy of
fish oil in the outcome of recurrent IgAN. In a recent
case report, however, the use of fish oil resulted in a
remarkable and prompt resolution of proteinuria and mi-
croscopic hematuria in a child with biopsy-proven post-
transplantation IgAN [99]. But no immunofluorescence
data from the patient’s native kidney biopsy were avail-
able, so it is not clear whether the IgA deposits found
in the renal transplant were recurrent or de novo in na-
ture. Larger controlled trials are definitely needed to fully
assess the overall impact of fish oil therapy in recurrent
IgAN.
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